Your browser doesn't support javascript.
loading
Reinitiating Chemotherapy beyond Progression after Maintenance Immunotherapy in Extensive-Stage Small-Cell Lung Cancer.
Rahnea-Nita, Roxana-Andreea; Toma, Radu-Valeriu; Grigorean, Valentin Titus; Coman, Ionut Simion; Coman, Violeta Elena; Plesea, Iancu Emil; Erchid, Anwar; Gorecki, Gabriel-Petre; Rahnea-Nita, Gabriela.
Afiliación
  • Rahnea-Nita RA; 8th Clinical Department-Radiology, Oncology and Hematology, Faculty of Medicine, "Carol Davila" University of Medicine and Phamacy, 020021 Bucharest, Romania.
  • Toma RV; Department of Oncology-Palliative Care, "Sf. Luca" Chronic Diseases Hospital, 041915 Bucharest, Romania.
  • Grigorean VT; 8th Clinical Department-Radiology, Oncology and Hematology, Faculty of Medicine, "Carol Davila" University of Medicine and Phamacy, 020021 Bucharest, Romania.
  • Coman IS; Department of Radiotherapy, "Prof. Dr. Alexandru Trestioreanu" Oncological Institute, 022328 Bucharest, Romania.
  • Coman VE; 10th Clinical Department-General Surgery, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Plesea IE; Department of General Surgery, "Bagdasar-Arseni" Clinical Emergency Hospital, 041915 Bucharest, Romania.
  • Erchid A; 10th Clinical Department-General Surgery, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Gorecki GP; Department of General Surgery, "Bagdasar-Arseni" Clinical Emergency Hospital, 041915 Bucharest, Romania.
  • Rahnea-Nita G; 10th Clinical Department-General Surgery, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Medicina (Kaunas) ; 60(8)2024 Jul 28.
Article en En | MEDLINE | ID: mdl-39202506
ABSTRACT

Introduction:

Small-cell lung cancer (SCLC) is an aggressive form of cancer with a poor prognosis. The two-year survival rate is 8% of all cases. Case presentation We present the case of a male patient who was 50 years old at the time of diagnosis in May 2022. He was diagnosed with extensive-stage small-cell lung cancer, treated with immunotherapy in combination with chemotherapy (Durvalumab in combination with Etoposide plus Carboplatin) as a first-line treatment, followed by maintenance immunotherapy. In December 2023, a PET-CT scan revealed progressive disease with multiple metastases. Chemotherapy was reinitiated with Etoposide plus Cisplatin in January 2024. After two cycles of chemotherapy, the patient developed post-chemotherapy anemia, for which treatment with Epoetinum alpha was initiated. Chemotherapy was continued for another five cycles, until May 2024, with the maintenance of hemoglobin at a level within 9.9 mg/dL-11 mg/dL. Upon assessment at the end of May 2024, the patient presented an ECOG = 2 performance status, with a moderate general state, moderate-intensity fatigue, no pain, no anxiety or depression and no dyspnea. Discussions, Literature Review and

Conclusions:

Reinitiating chemotherapy after the failure of maintenance immunotherapy may be an option in patients with SCLC. Epoetinum allows oncological treatment by preventing chemotherapy-induced anemia.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Pulmonar de Células Pequeñas / Inmunoterapia / Neoplasias Pulmonares Límite: Humans / Male / Middle aged Idioma: En Revista: Medicina (Kaunas) Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Rumanía Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Pulmonar de Células Pequeñas / Inmunoterapia / Neoplasias Pulmonares Límite: Humans / Male / Middle aged Idioma: En Revista: Medicina (Kaunas) Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Rumanía Pais de publicación: Suiza